508 filings
Page 9 of 26
S-8
dzgeh
9 Aug 17
Registration of securities for employees
12:00am
8-K
9tsubtddhm
9 Aug 17
Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity
12:00am
8-K
g5n3lsu5l69o4
6 Jun 17
Regulation FD Disclosure
12:00am
8-K
ogfbctmo ki1atp6
25 May 17
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
12:00am
424B5
t852499
25 May 17
Prospectus supplement for primary offering
12:00am
424B5
5ekba
23 May 17
Prospectus supplement for primary offering
12:00am
8-K
oc33d 6x525lzx6ss
9 May 17
Departure of Directors or Certain Officers
12:00am
8-K
scv0uxsygt3lq 4o0
5 May 17
Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
12:00am
S-3ASR
s5vprjw4ac av11
5 May 17
Automatic shelf registration
12:00am
8-K
bxacdxtb
8 Feb 17
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity
12:00am
CT ORDER
g9xzk35
7 Feb 17
Confidential treatment order
12:00am
8-K
n969w
3 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
fmpe0b 44jmg1c
2 Nov 16
Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity
12:00am
8-K
dv8cz1m4qchsiu1fqu
5 Oct 16
Alnylam Pharmaceuticals Discontinues Revusiran Development
12:00am
8-K
rkmhf4jxa21cptvujq
19 Sep 16
Alnylam Expands and Strengthens Management Team as it Plans for Commercialization
12:00am